HER2 PLAYS A CENTRAL ROLE IN MULTIPLE TUMOR TYPES^1-3

HER = human epidermal growth factor receptor; mCRC = metastatic colorectal cancer.

References: 1. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007;97(4):453-457. 2. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264-275. 3. Siena S, Sartore-Bianchi A, Marsoni S, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108-1119. 4. Ross JS, Ali SM, Elvin JA, et al. Targeted therapy for HER2 driven colorectal cancer. J Clin Oncol. 2017;35(15 suppl):3583-3583. 5. Bang Y-J, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010;376(9749):1302]. Lancet. 2010;376(9742):687-697. 6. Martínez-Sáez O, Prat A. Current and future management of HER2-positive metastatic breast cancer. JCO Oncol Pract. 2021;17(10):594-604. 7. Kang A, Bloudek L, Mordi U, et al. Systematic literature review of HER2 amplification/overexpression in colorectal cancer. Poster presented at: Academy of Managed Care Pharmacy Nexus; October 18-21, 2021; Denver, Colorado. 8. Zhao J, Xia Y. Targeting HER2 alterations in non–small-cell lung cancer: a comprehensive review. JCO Precis Oncol. 2020;4:411-425